Our actual future results may differ materially from our current expectations due to the risks and uncertainties inherent our business. These risks are detailed under Risk Factors in our most recent Form 10-Q and elsewhere in our periodic reports and other filings made with the Securities and Exchange Commission from time-to-time. All forward-looking statements are qualified in their entirety by this cautionary statement which is made under the Safe Harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and we undertake no obligation to revise or update the information discussed during this call to reflect events and circumstances after this call.
If anyone has not seen our press release issued today, you can access it on our website at www.cadencepharm.com. We also post and maintain the current version of our corporate presentation on the Investors portion of our website under events and presentations and then corporate overview. Additionally, this conference call is being webcast through our website and will be archived there for future reference. We use the Investors portion of our website as one means of disclosing material non-public information, so we encourage investors to monitor our website in addition to following our press releases, SEC filings and public conference calls and webcasts.
Ted SchroederThanks Bill. Good afternoon and thank you for joining us today. I will open by providing a brief overview of the second quarter next Scott will provide an update on our commercial activities for OFIRMEV and then Bill will discuss our financial results. Following our prepared remarks, we will open the call to your questions. I am very pleased to report that we had a strong second quarter achieving net product revenue growth of 38% compared to the first quarter of 2012; importantly our net product revenue of $11.1 million for the quarter exceeded the financial guidance that we provided last quarter. We believe we are effectively executing on our sales and marketing strategy and that the adoption of OFIRMEV will continue to generate strong revenue growth.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV